Damora Therapeutics (DMRA) Net Income towards Common Stockholders Growth (1y) (2020 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -58.11% |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -95.76% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -290.15% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 59.59% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -129.68% |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -10.08% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 1,228.66% |
| 10 | Damora Therapeutics | 853.36 Mn | 650.97 Mn | - | -996.84% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -996.84% |
| Dec 31, 2025 | -4,376.19% |
| Sep 30, 2025 | 19.31% |
| Jun 30, 2025 | 35.61% |
| Mar 31, 2025 | 53.75% |
| Dec 31, 2024 | 171.10% |
| Sep 30, 2024 | 52.27% |
| Jun 30, 2024 | 50.32% |
| Mar 31, 2024 | 59.41% |
| Dec 31, 2023 | 52.13% |
| Sep 30, 2023 | 40.27% |
| Jun 30, 2023 | 37.25% |
| Mar 31, 2023 | 20.35% |
| Dec 31, 2022 | -0.42% |
| Sep 30, 2022 | -7.29% |
| Jun 30, 2022 | -39.56% |
| Mar 31, 2022 | -24.99% |
| Dec 31, 2021 | -242.78% |
| Sep 30, 2021 | 11.61% |
| Jun 30, 2021 | -93.56% |
| Mar 31, 2021 | -132.45% |
| Dec 31, 2020 | 84.79% |
| Sep 30, 2020 | -160.88% |